Heron Therapeutics (NASDAQ: HRTX) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Heron Therapeutics to related companies based on the strength of its dividends, profitability, risk, valuation, institutional ownership, earnings and analyst recommendations.
Insider and Institutional Ownership
48.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 19.9% of Heron Therapeutics shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Heron Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Heron Therapeutics Competitors||-3,989.00%||-119.24%||-44.05%|
Valuation and Earnings
This table compares Heron Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Heron Therapeutics||$13.42 million||-$174.14 million||-3.86|
|Heron Therapeutics Competitors||$207.80 million||-$2.20 million||0.14|
Heron Therapeutics’ rivals have higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Heron Therapeutics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500. Comparatively, Heron Therapeutics’ rivals have a beta of 1.63, suggesting that their average stock price is 63% more volatile than the S&P 500.
This is a summary of current recommendations for Heron Therapeutics and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Heron Therapeutics Competitors||465||2216||6112||117||2.66|
Heron Therapeutics presently has a consensus price target of $30.11, indicating a potential upside of 83.05%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.27%. Given Heron Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Heron Therapeutics is more favorable than its rivals.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.